About Syncona
Syncona is a publicly listed company based in London (United Kingdom) founded in 2012. Healthcare investments are managed via private equity by Syncona. Syncona has completed 4 acquisitions, including Applied Genetics Technologies Corporation, Freeline and Omass. Syncona offers products and services including Investment Management and Portfolio Development. Its focus areas include Investment Industry, Private Equity Funds and Growth Equity. Its legal entity is Syncona Limited.
Company details
Syncona was founded in 2012 and is headquartered in London, United Kingdom. Focus is placed on private equity investments within the healthcare sector, where portfolio companies are supported through funding and strategic guidance. Operations encompass identifying and nurturing early-stage biotechs and medtech firms, with a team of partners and directors overseeing activities from the UK base. Services include capital deployment and operational expertise for healthcare innovators.
- Headquarters London, United Kingdom
- Stage Public
- SectorsFinancial Services
- Email••••••••
- Phone•••• ••••
- Website synconaltd.com
- Social LinkedIn X YouTube
- Legal Name Syncona Ltd Gbp
- Annual Revenue$75.93 M (USD)-40.88as on Mar 31, 2026
- Net Profit-$11.65 M (USD)93.85as on Mar 31, 2026
- EBITDA-$9.04 M (USD)95.2as on Mar 31, 2026
- Investments & Acquisitions
Products & Services of Syncona
Syncona offers a comprehensive portfolio of products and services, including Investment Management and Portfolio Development.
Investments are managed in life science companies to support development of therapeutics
Portfolios are developed by building and overseeing biotechnology firms across clinical stages
Apps and channels of Syncona
its YouTube channel Syncona LTD has 42 subscribers and 26 videos.
Videos from Syncona
The most watched videos on Syncona's YouTube channel, Syncona LTD (42 subscribers). Click a video to play it here.
More on Syncona LTD.
People of Syncona
37 people are tracked at Syncona (18 in leadership, 6 in board & advisors, 13 in team).
| Name | Role | Group |
|---|---|---|
Rob Hutchinson | Chairman | Leadership |
Kemal Malik | Non Executive Director | Leadership |
Julie Cherrington | Board Member | Leadership |
John Roche | Non Executive Director | Leadership |
Gian Piero Reverberi | Non Executive Director | Leadership |
Cristina Csimma | Non Executive Director | Leadership |
Nikki Padden | Partner | Leadership |
Kate Butler | CFO | Leadership |
Harriet Gower Isaac | Chief People Officer | Leadership |
Ben Woolven | Operations Partner | Leadership |
Magdalena Jonikas | Lead Partner | Leadership |
Chris Hollowood | CEO | Leadership |
Michael Kyriakides | Investment Partner | Leadership |
Elisa Petris | Lead Partner | Leadership |
Fiona Langton-Smith | Chief Human Resources Officer | Leadership |
John Tsai | Executive Partner | Leadership |
Annabel Clark | Head, Investor Relations & Communications | Leadership |
Nia Dadson | Head Of Governance | Leadership |
Charles Swanton | Founder | Board & advisors |
Karl Peggs | Founder | Board & advisors |
17 more people are available in the full profile.
Complete people profiles for Syncona
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Syncona
Syncona is a publicly listed company on the LSE with ticker symbol SYNC in UK, operating in the Miscellaneous sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date26 Oct 2012
- Listed onLSE: SYNC
- Listed entitySyncona Ltd GBP
- Exchange sectorMiscellaneous
- ISINGG00B8P59C08
- Share price123.96 GBX (+0.29% on the day) · 2026-10-14
- Market capitalisation754,159,320.00 GBX
- EPS (diluted, trailing year)-0.01 GBX
- Volume (last session)2,282
Financials of Syncona
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 57.3M GBP | -8.8M GBP | -6.8M GBP |
| 2024 | 97.0M GBP | -143.2M GBP | -142.4M GBP |
| 2023 | 58.6M GBP | 3.8M GBP | 4.2M GBP |
| 2022 | 41.6M GBP | -56.0M GBP | -54.4M GBP |
| 2021 | 39.5M GBP | 8.8M GBP | 11.2M GBP |
Detailed financial statements for Syncona
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Syncona
Syncona has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Applied Genetics Technologies Corporation, Freeline and Omass.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Gene therapy platform is developed for chronic disease treatments. | freeline.life | Stevenage, United Kingdom | 2015 | Nov 2023 | •••• | |
Clinical-stage biotech company advancing gene therapies for rare and neurological diseases. | spurtherapeutics.com | Stevenage, United Kingdom | 2015 | Nov 2023 | •••• | |
Developer of gene therapies for rare eye diseases caused by mutated genes | agtc.com | Alachua, United States | 1999 | Oct 2022 | •••• | |
Native mass spectrometry services for protein characterization are provided. | omasstech.com | Oxford, United Kingdom | 2016 | Nov 2018 | $192.7M |
Complete acquisition details for Syncona
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Syncona
6 dated milestones of Syncona across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Syncona is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Omass.
- Acquisition Acquires Applied Genetics Technologies Corporation.
- Acquisition Acquires Spur Therapeutics.
- Acquisition Acquires Freeline.
Web traffic of Syncona
The website of Syncona (synconaltd.com) receives about 6.7K visits a month.
- Monthly visits6.7K
▼ 10.7% vs previous month
Websites whose visitors overlap most with Syncona. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| mosaic.tech | 100% | 7.6K | #780,506 | View details | |
annualreports.com | annualreports.com | 100% | #135,230 | – | |
| spurtherapeutics.com | 35% | 8.7K | #2,887,501 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Syncona
Complete news archive for Syncona
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Syncona
Syncona was founded in 2012.
Syncona is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Annual revenue of Syncona is $75.93M as on Mar 31, 2026.
Syncona was founded in 2012 and is headquartered in London, United Kingdom. Focus is placed on private equity investments within the healthcare sector, where portfolio companies are supported through funding and strategic guidance. Operations encompass identifying and nurturing early-stage biotechs and medtech firms, with a team of partners and directors overseeing activities from the UK base. Services include capital deployment and operational expertise for healthcare innovators.
Syncona offers Investment Management and Portfolio Development.
Yes, Syncona is publicly traded on LSE under the ticker symbol SYNC.
Syncona has made 4 acquisitions, including Applied Genetics Technologies Corporation, Freeline, and Omass.
Syncona operates through Syncona Limited.